Tamoxifen Inhibits Arterial Accumulation of LDL Degradation Products and Progression of Coronary Artery Atherosclerosis in Monkeys
- 1 February 1997
- journal article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 17 (2) , 403-408
- https://doi.org/10.1161/01.atv.17.2.403
Abstract
Estrogen replacement therapy reduces the risk of coronary heart disease in postmenopausal women and inhibits progression of coronary artery atherosclerosis in monkeys. Tamoxifen is a nonsteroidal compound with mixed estrogen agonist and antagonist properties. Its antagonist activity is useful in chemotherapy of breast cancer and may have protective effects on plasma lipid concentrations, but its effects on atherogenesis have not been defined. The goal of this study was to examine the effect of tamoxifen on plasma lipids, arterial and hepatic LDL metabolism, and progression of coronary artery atherosclerosis in surgically postmenopausal female monkeys. Thirty-five monkeys were fed an atherogenic diet containing 1.3 mg·kg −1 ·d −1 tamoxifen (equivalent to the usual dose of 20 mg/d given to women). Thirty-one monkeys were fed the same atherogenic diet with no tamoxifen. Ten monkeys from each treatment group were fed the test diets for 12 weeks to examine the short-term effects of tamoxifen on arterial LDL metabolism. The rest of the monkeys were fed the test diets for 3 years to study the long-term effects of tamoxifen on development of atherosclerosis. In the short term, tamoxifen inhibited the rate of arterial accumulation of LDL degradation products overall ( P =.03) and decreased hepatic cholesterol content ( P =.003). In the long term, tamoxifen increased plasma concentrations of triglycerides (0.60±0.67 versus 0.23±0.02 mmol/L, P =.001) and reduced average LDL molecular weight (5.3±0.2 versus 4.8±0.1 g/μmol, P =.004) but had no effects on plasma total, LDL, or HDL cholesterol concentrations. Coronary artery atherosclerosis (intimal area, mean±SEM) was 0.25±0.06 mm 2 in control monkeys and 0.12±0.03 mm 2 in tamoxifen-treated monkeys ( P =.057). We conclude that tamoxifen has antiatherogenic effects that may be modulated in part through direct effects on arterial LDL metabolism.Keywords
This publication has 35 references indexed in Scilit:
- Estrogen modulates the inducible expression of platelet-derived growth factor mrna by monocyte/macrophagesLife Sciences, 1995
- Estrogen and the blood vessel wallCurrent Opinion in Cardiology, 1994
- 17 beta-Estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism.Journal of Clinical Investigation, 1994
- The case for clinical trials of tamoxifen for prevention of breast cancerThe Lancet, 1992
- Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit.Journal of Clinical Investigation, 1992
- Long term effects of tamoxifen on blood lipid values in breast cancer.BMJ, 1992
- TAMOXIFEN USE, OESTROGEN BINDING AND SERUM LIPIDS IN POSTMENOPAUSAL WOMEN WITH BREAST CANCERAnz Journal of Surgery, 1990
- Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Effects of estrogen on low density lipoprotein metabolism in males. Short-term and long-term studies during hormonal treatment of prostatic carcinoma.Journal of Clinical Investigation, 1989
- Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two yearsBreast Cancer Research and Treatment, 1988